Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. AREAS COVERED: We review the therapeutic mechanisms behind both conventional and psychedelic paradigms, including the evolution of this knowledge and the associated explanatory frameworks. We explore how psychedelics have provided insights about psychiatric illnesses and treatments over the past decades. We discuss limitations to early explanatory models while highlighting and comparing the psychological and biological mechanisms underlying many psychiatric treatments. METHODS: , 2020, and iterative retrieval of references from recent reviews and clinical trials. EXPERT OPINION: The contextual model of the common factors of psychotherapy provides a powerful perspective on psychotherapy, antidepressants, and psychedelics, as well as 3,4-methylenedioxymethamphetamine (MDMA) and ketamine. It aligns well with key tenets of psychedelic-assisted psychotherapy. Conventional antidepressants and especially psychedelics may improve the efficacy of psychotherapy via neurochemical changes and increased environmental sensitivity. Combined treatments hold significant promise for advancing the knowledge and treatment of many forms of psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ketamine seems to be mainly offered as a stand-alone pharmacological treatment, like conventional antidepressants (Greenway et al., 2020).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Greenway et al., 2020
Citations
Cites
1 retracted
Items 201–219 of 219
Treatment of depression with antidepressants is primarily a psychological treatment.
Ankarberg, P., & Falkenström, F. (2008) · Psychotherapy · doi:10.1037/a0013309 · Cited by 34 · cited 1×
“Such findings have led some to argue that the treatment of depression by antidepressants is primarily a psychological treatment [102], but alternative explanations”
BackgroundOrsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., Martinotti, G., Vellante, F., Matarazzo, I., et al. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161025140111 · Cited by 33 · cited 1×
“With some notable exceptions, like brexanolone infusions for postpartum depression and vortioxetine for major depressive disorder [17,18], these developments appear to represent the only recent”
BackgroundNew Statistics on the Cost of New Drug Development and the Trouble with CNS Drugs
Lindsley, C. W. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500298z · Cited by 32
Peak Experiences: Investigation of Their Relationship to Psychedelic Therapy and Self-Actualization
Klavetter, R. E., & Mogar, R. E. (1967) · Journal of Humanistic Psychology · doi:10.1177/002216786700700206 · Cited by 30
Heifets, B. D., & Malenka, R. C. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1145 · Cited by 29 · cited 2×
“Their highly distinct properties are broached below, but they share the capacity to engender powerful temporary alterations in consciousness that may hold therapeutic potential [19,20].”
BackgroundBreakthrough-Therapy Designation — An FDA Perspective
Corrigan‐Curay, J., McKee, A. E., & Stein, P. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1801222 · Cited by 22 · cited 1×
“available therapies for life-threatening illnesses’ [11].”
LSD Reconsidered: Should clinical research be resumed?
Grinspoon, L. (1981) · The Sciences · doi:10.1002/j.2326-1951.1981.tb01901.x · Cited by 21
Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission
Lür, G., Fariborzi, M., & Higley, M. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213721 · Cited by 21 · cited 1×
“receptor (NMDA) antagonist that modulates glutamergic transmission [167], though it is active at a large variety of”
BackgroundMcAndrew, A., Lawn, W., Stevens, T., Porffy, L., Brandner, B., & Morgan, C. J. A. (2017) · Trials · doi:10.1186/s13063-017-1895-6 · Cited by 20 · cited 1×
“explanations may partly underly these results [234], but cannot fully explain how ketamine exerts anti-addiction effects”
Psychiatry might need some psychedelic therapy
Johnson, M. W. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1509544 · Cited by 17 · cited 2×
“Some authors argue that the rise in prescription is due to excessive biomedicalization of psychiatric illness over the preceding decades [62].”
BackgroundWentink, C., Huijbers, M. J., Lucassen, P. L., Kramers, C., Akkermans, R., Adang, E., Spijker, J., & Speckens, A. E. M. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0989-5 · Cited by 15
Goldstone, D. (2016) · South African Journal of Psychology · doi:10.1177/0081246316653860 · Cited by 10 · cited 2×
“other hand, partly aims to change patients’ problematic patterns of relating to their selves and to others via developing insight about past relationships and their relationship with the therapist [90].”
BackgroundRubio-Valera, M., Peñarrubia‐María, M. T., Iglesias-González, M., Knapp, M. R. J., McCrone, P., Roig, M. B., Sabés-Figuera, R., Luciano, J. V., Mendive, J. M., Murrugarra-Centurión, A. G., et al. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01034-5 · Cited by 10
Ballesta, S., Reymond, G., Pozzobon, M., & Duhamel, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147136 · Cited by 8 · cited 1×
“One of the results appears to be greater prosocial behavior [163,164].”
BackgroundCombined Pharmacotherapy and Psychological Treatment for Depression: A Systematic Review
Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.714 · Cited by 5
Stockings, G. T. (1940) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-194011000-00034 · Cited by 4
Hewitt, K. (2016) · History of Science · doi:10.1177/0073275316674724 · Cited by 4 · cited 2×
“This hypothesis has since been essentially discarded, but the shift toward a biological perspective set the stage for the first commercial antipsychotics in 1952 [32,125], which have since superseded psycho-”
BackgroundListening to Prozac: A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self
Elliott, C. E. (1994) · BMJ · doi:10.1136/bmj.308.6945.1724 · Cited by 2
From ‘Pathological Motherhood’ to Refrigerator Mothers
Waltz, M. (2013) · Palgrave Macmillan UK eBooks · doi:10.1057/9781137328533_5 · Cited by 1
Research works printed but not linked: 22
- Friedrich MJ., 2017, JAMA, 317, 1517
- Bahr R, 2019, P T Peer-Rev. J. Formul. Manag, 44, 340
- Lee MA, 1992, Acid dreams: the complete social history of LSD: the CIA, the sixties, and beyond. Rev. Evergreen ed
- Andrews PW, Front. Psychol
- Kirsch I, Front. Psychiatry
- Hengartner MP. Methodological Flaws, 2017, Front. Psychiatry, 8:275
- Østergaard SD, 2017, Acta Neuropsychiatr
- Sansone RA, 2012, Clin Neurosci, 9, 41
- Davies J, 2019, Behav, 97, 111
- Freud S, 2007, The history of the psychoanalytic movement
- Kirsch I, 2002, Food and Drug Administration. Prev. Treat, 5
- Zilcha-Mano S, 2015, Psychosom, 84, 177
- Kaplan RM, Int J Humanit Soc Sci Educ
- Ban TA, 2007, Neuropsychiatr Dis Treat, 3, 495
- Hurth KP, 2020, Care Med, 1
- Glue P, 20, J Psychopharmacol (Oxf.)
- Kasprow MC, 1999, J Psychother P Res, 8, 12
- Taking Psychedelics BI, 2018, Med, 21, 417
- Winnicott DW, 1953, Int J Psychoanal, 34, 89
- Thiessen MS, 2018, J Psychopharmacol (Oxf.), 026988111877178
- Ross C, 2019, Ann Clin Psychiatry, 31, 271
- Sos P, 2013, Neuro Endocrinol Lett, 34, 287
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Schimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
“Ketamine seems to be mainly offered as a stand-alone pharmacological treatment, like conventional antidepressants (Greenway et al., 2020).”
BackgroundThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Metadata
- Authors
- Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A.
- Affiliations
- McGill University (CA)
- Data Services, MAPS Public Benefit Corporation
- Project New Day, Psychedelic.Support
- Corresponding author
- Greenway, Kyle T.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2020-06-01
- Volume
- 13
- Issue
- 6
- Pages
- 655-670
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3031742716
- Semantic Scholar
- 82347e6b820aa8a3f6105d3ae1955c2a08f52eae
- Cited by
- 94
- References
- 217
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 27 · 2023: 14 · 2022: 13 · 2021: 10 · 2020: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- psychedelic-assisted psychotherapy, antidepressants, therapeutic mechanisms, MDMA, ketamine, psychedelics, environmental sensitivity, neurochemical changes, psychopathology
- MeSH terms
- Animals, Mental Disorders, Combined Modality Therapy, Hallucinogens, Humans, Psychotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.